Phillip Palmbos, MD, PhD, assistant professor, University of Michigan Health, discusses the current state of chemoimmunotherapy use in patients with bladder cancer. Palmbos explains that sequential use of chemotherapy and immunotherapy in patients with locally advanced or metastatic urothelial cancer has emerged as an option following positive overall survival (OS) data from the phase 3 JAVELIN Bladder 100 trial (NCT02603432), which assessed maintenance avelumab (Bavencio) following frontline chemotherapy in this patient population. However, Palmbos says that combined chemoimmunotherapy still cannot be recommended because findings from the phase 3 IMvigor130 (NCT02807636) and KEYNOTE-361 (NCT02853305) trials did not demonstrate an OS benefit with simultaneous chemoimmunotherapy in patients with bladder cancer. Ongoing research is attempting to clarify the role of the treatment approach in this setting.
Cell therapy TARA-002 shows initial promise in NMIBC
April 9th 2024"This encouraging anti-tumor activity coupled with a favorable safety profile and mode of administration that is both convenient and familiar to urologists indicates that, if confirmed in future studies, TARA-002 could potentially play a meaningful role in NMIBC treatment in the future," says Timothy D. Lyon, MD.
Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app
December 7th 2021“It's not a replacement for clinical judgment, obviously. But at the end of the day, the idea is that it shows you what your next steps are based on what the American Urological Association and [Society of Urologic Oncology] guidelines are for non-muscle invasive bladder cancer,” Chad R. Ritch, MD, MBA, FACS.
Nadofaragene firadenovec shows durable efficacy in NMIBC
April 8th 2024"In this follow-up analysis of the phase 3 study, we demonstrated a sustained response to Adstiladrin treatment over 3 years, allowing more than half of the patients in the study to remain cystectomy free for at least 36 months,” says Colin P.N. Dinney, MD.